biosimilars for ibd: when to start, switch, or stay away?
Published 4 years ago • 775 plays • Length 23:20Download video MP4
Download video MP3
Similar videos
-
18:23
biosimilars for ibd: to start, switch, or stay away?
-
20:47
biosimilars for ibd: start, switch, or stay away?
-
16:48
biosimilars in ibd: where do we stand today?
-
39:51
why ibd patients should know about biosimilars
-
16:44
the current landscape of biosimilars in ibd
-
4:04
biosimilars and inflammatory bowel disease
-
7:16
being on inflectra after being on remicade with crohns disease
-
8:07
biosimilars | what is a biosimilar? | gastrointestinal society
-
6:46
inflammatory bowel disease (ibd)
-
10:00
ibd clinical case: the process of switching from a reference biologic to a biosimilar
-
2:23
what to know before switching from biologics to biosimilars?
-
5:34
ibd: switching from a biologic to a biosimilar
-
16:22
incorporating ibd biosimilars into practice: patient care and education
-
32:29
keynote speaker: understanding the monitoring and safety of ibd medications and biologics
-
1:21
biosimilars: terms to know
-
1:22:22
making the switch from biologics to biosimilars in ibd: knowledge over skepticism
-
1:35
biosimilars: safety & efficacy
-
1:47
understanding biosimilars - for ibd patients
-
13:19
what are biosimilar therapies and why should we care?
-
11:40
debate: biosimilar therapies - caution, more studies are needed
-
22:15
biosimilars: what patients and caregivers need to know
-
20:40
patient care in ibd: incorporating biosimilars into clinical practice